Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 75 years~* French citizen~* Signed consent for participation~* No dental infection~* No programmed dental surgery during the treatment~* Effective contraception for women of childbearing potential~* Patient with advanced otosclerosis defined by:~* Slowly progressive uni or bilateral hearing loss~* No past medical history of chronic otitis media~* No past medical history of other causes of cochlear damage (significant surgical trauma with a 30 dB deterioration of bone conduction at 4000 Hz in postoperative period, sound trauma, barotrauma, ototoxic drugs)~* Normal tympanic membranes~* A conductive or mixed hearing loss~* A moderate to severe hearing loss on at least one ear (average of thresholds at 500, 1000, 2000 and 4000 Hz) on air conduction between 30 and 90 dB.~* Normal tympanometry or with a decreased peak~* Absent ipsilateral stapedial reflex~* As possible, intraoperative confirmation of stapediovestibular ankylosis~* radiological confirmation if CT-scan before inclusion available~Exclusion Criteria:~* Individuals not covered by the french public health insurance~* Pure-tone average \< 30 dB ou \> 90 dB~* Programmed stapes surgery during the observation period~* Previous treatment by biphosphonate~* Known intolerance to tiludronate~* Other contraindications to tiludronate treatment:~* allergy to biphosphonates~* hypersensitivity to one of the excipients~* severe renal failure (creatinine clearance \< 30 mL/min)~* juvenile Paget's disease~* pregnancy and breastfeeding~* galactose intolerance, lactase insufficiency, glucose-galactose malabsorption~* Ongoing chemotherapy or radiotherapy or patient achieves of a cancer~* Long-term systemic steroid treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Skelid (Type: EXPERIMENTAL): tiludronic acid
- Control (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).